De-Risking the Human Translatability Piece of Next-Generation Vectors

Time: 8:35 am

Details:

• Highlighting different approaches to produce robust, translatable data when transitioning through preclinical studies
• Better understanding disease mechanisms and anticipated clinical responses to guide vector selection and design
• Exploring more predictive preclinical models (e.g., human cells, organoids, assembloids) for both vector validation and development
• Outlining the role of vector bioengineering for fit-for-purpose human tissue types
• Reducing the number of animal model studies to lower costs, while maintaining good clinical translatability